Gapping up
In reaction to strong earnings/guidance:
- CVRS +76%, PSV +66.7%, VSI +40.7%, CVNA +17.9%, ROKU +17.5% (also MSCI World Index addition news), STMP +16.9%, APYX +15.9%, TLND +15.5%, FSCT +13.9%, NTRA +13.5%, INFN +12.1%, UPLD +10.5%, GOGO +10.1%, NBEV +10.1%, JACK +9.6%, CPA +9.4%, DAR +9.2%, CRON +8.8%, RLGY +8.7%, G +8.6%, NUAN +8.6%, AVLR +8.1%, GTE +7.6%, KTB +7.1%, LYFT +7%, AAOI +6.6%, RGNX +6.1% (also reports additional "positive" interim Phase 1/2a trial update for RGX-314 for the treatment of Wet AMD), FSM +6%, ALB +5.8%, ORA +5.8%, AMC +5.8%, REPH +5.6%, BKNG +5.4%, PETQ +5.3%, CRBP +5.3%, CEVA +5.2%, DERM +5.1%, UPWK +5%, CAH +5%, ADMA +4.5%, MGA +4%, MUR +4%, AIG +3.8%, BW +3.8%, CLMT +3.8%, MRO +3.7%, TELL +3.6%, PRGO +3.5%, ENS +3.4%, NTES +3.3%, FOLD +3.2%, KDP +3.2%, SONO +3%, ELF +3%, ET +2.8%, FVRR +2.8%, NBRV +2.8%, RDUS +2.2%, AXSM +2.2%, OPK +2.1%, VERI +2.1%, AZPN +1.9%, TTGT +1.9%, PTE +1.8%, TW +1.8%, BAM +1.5%, EPAM +1.3%, MELI +1.1%, ZVO +1%, NICE +1%, .
M&A news:
- CVRS +76% (to be acquired by Siemens Healthineers for $4.28 per share)
- AVDR +29% (Avedro to be acquired by Glaukos in an all-stock transaction)
- HUN +14.9% (divests chemical intermediates and surfactants businesses to Indorama Ventures for $2.1 bln)
Other news:
- DBVT +16.8% (submits BLA to FDA for Viaskin Peanut for the treatment of peanut allergy)
- SYMC +12.7% (on reports that the company is near a deal to sell its Enterprise business to Broadcom (AVGO) for ~$10 bln)
- CLDR +3.7% (Carl C. Icahn increases active stake)
- DISH +3.1% (Chairman disclosed the purchase of ~500K shares)
- TWLO +0.9% (Director Jeffrey Immelt bought 8.5K shares)
Analyst comments:
- HTZ +3.6% (upgraded to Overweight from Equal Weight at Barclays)
- SHSP +3.5% (upgraded to Overweight from Equal-Weight at Stephens)
- FL +1% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
- MDLZ +0.8% (upgraded to Overweight at Morgan Stanley)
- OHI +0.8% (upgraded to Strong Buy from Outperform at Raymond James)